Strategies to Maximize the Clinical Benefit of EGFR TKIs in Advanced NSCLC

Strategies to Maximize the Clinical Benefit of EGFR TKIs in Advanced NSCLC (May 2019)

Friday, May 31, 2019 in Chicago, Illinois
Dinner -- Sheraton Grand Chicago, 6:30 PM CT
Chicago Ballroom VI (Ballroom Level)


Welcome and Overview

Selecting First-line Therapy in the Setting of EGFR-Mutated NSCLC (Case Discussion)

Selecting Second-line Therapy and Beyond in the Setting of EGFR-Mutated NSCLC (Case Discussion)

Future Directions in Treatment Strategies for EGFR-Mutated NSCLC

Conclusions and Final Question and Answer Session


Program Director
Shirish M. Gadgeel, MD

Mary Lou Kennedy Research Professor in Thoracic Oncology
, Thoracic Oncology Research Program
Associate Director, Cancer Care at Networking and Affiliation Centers
Division of Hematology/Oncology
Department of Internal Medicine
University of Michigan
Ann Arbor, Michigan

Heather Wakelee, MD

Professor of Medicine, Oncology
Department of Medicine/Oncology
Stanford University/Stanford Cancer Institute
Stanford, California

Helena A. Yu, MD

Associate Attending
Department of Medicine
Section Head, Molecular Targets in Lung Cancer
Memorial Sloan Kettering Cancer Center
New York, New York

Goal Statement
The goal of this activity is to improve participants’ knowledge of and competence in applying EGFR inhibitors in the treatment of patients with EGFR-mutated non-small-cell lung cancer.

Target Audience 
This program is intended for physicians, oncology nurses, pharmacists, and other healthcare providers who care for patients with non-small-cell lung cancer.

Learning Objectives 

  • Apply expert recommendations for frontline therapy for advanced EGFR-mutated NSCLC focusing on safety, efficacy, and the individualization of therapy based on tumor-specific and patient-specific factors
  • Compare the efficacy and safety of first-generation EGFR TKIs with later-generation EGFR TKIs
  • Examine current recommendations for molecular testing and the roles for liquid biopsies in guiding the use of EGFR TKI therapy
  • Plan optimal sequencing of EGFR TKIs after considering the available evidence and expert recommendations
  • Evaluate current and evolving treatment approaches to address acquired resistance and progression in advanced EGFR-mutated NSCLC


Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Clinical Care Options, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 2.0 contact hours.

Pharmacist Continuing Education

Credit Designation
Postgraduate Institute for Medicine designates this continuing education activity for 2.0 contact hours (0.2 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008162-9999-760-L01-P)

Type of Activity: Knowledge

Disclosure of Conflicts of Interest 
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.